Chile Pharma IPO Seen H1

Chile’s Laboratorios Recalcine is expected to begin roadshowing an IPO near the end of March or at the beginning of April, according to a source close to the matter. This would likely put the IPO in April or May. Recalcine, which filed initial papers for the deal in January, is expected to raise at least a $200m-equivalent minimum. Proceeds are to be used for new acquisitions. Recalcine, which has a presence in 16 LatAm countries and is controlled by CEO Alejandro Weinstein bought Argentina’s Northia in July for $25m, after buying 49% of UK-based Allergy Therapeutics for GBP22m in 2009. LarrainVial is managing the deal. Fishery AcquaChile is another which has indicated its IPO intentions, with a deal through IMTrust expected in the second half of the year.